Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)

This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTC...

Descripción completa

Detalles Bibliográficos
Autores principales: Dioverti, Veronica, Boghdadly, Zeinab El, Shahid, Zainab, Waghmare, Alpana, Abidi, Maheen Z., Pergam, Steven, Boeckh, Michael, Dadwal, Sanjeet, Kamboj, Mini, Seo, Susan, Chemaly, Roy F., Papanicolaou, Genovefa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. 2022
Materias:
Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464362/
https://www.ncbi.nlm.nih.gov/pubmed/36103987
http://dx.doi.org/10.1016/j.jtct.2022.09.002
_version_ 1784787566251212800
author Dioverti, Veronica
Boghdadly, Zeinab El
Shahid, Zainab
Waghmare, Alpana
Abidi, Maheen Z.
Pergam, Steven
Boeckh, Michael
Dadwal, Sanjeet
Kamboj, Mini
Seo, Susan
Chemaly, Roy F.
Papanicolaou, Genovefa A.
author_facet Dioverti, Veronica
Boghdadly, Zeinab El
Shahid, Zainab
Waghmare, Alpana
Abidi, Maheen Z.
Pergam, Steven
Boeckh, Michael
Dadwal, Sanjeet
Kamboj, Mini
Seo, Susan
Chemaly, Roy F.
Papanicolaou, Genovefa A.
author_sort Dioverti, Veronica
collection PubMed
description This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) and is an update of pervious publication. Since our original publication in 2020, the NIH and IDSA have published extensive guidelines for management of COVID-19 which are readily accessible ( NIH Guidelines , IDSA Guidelines ). This update focuses primarily on issues pertaining specifically to HCT/cellular therapy recipients. Information provided in this manuscript may change as new information becomes available.
format Online
Article
Text
id pubmed-9464362
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-94643622022-09-12 Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022) Dioverti, Veronica Boghdadly, Zeinab El Shahid, Zainab Waghmare, Alpana Abidi, Maheen Z. Pergam, Steven Boeckh, Michael Dadwal, Sanjeet Kamboj, Mini Seo, Susan Chemaly, Roy F. Papanicolaou, Genovefa A. Transplant Cell Ther Guideline This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) and is an update of pervious publication. Since our original publication in 2020, the NIH and IDSA have published extensive guidelines for management of COVID-19 which are readily accessible ( NIH Guidelines , IDSA Guidelines ). This update focuses primarily on issues pertaining specifically to HCT/cellular therapy recipients. Information provided in this manuscript may change as new information becomes available. The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. 2022-12 2022-09-11 /pmc/articles/PMC9464362/ /pubmed/36103987 http://dx.doi.org/10.1016/j.jtct.2022.09.002 Text en © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Guideline
Dioverti, Veronica
Boghdadly, Zeinab El
Shahid, Zainab
Waghmare, Alpana
Abidi, Maheen Z.
Pergam, Steven
Boeckh, Michael
Dadwal, Sanjeet
Kamboj, Mini
Seo, Susan
Chemaly, Roy F.
Papanicolaou, Genovefa A.
Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
title Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
title_full Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
title_fullStr Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
title_full_unstemmed Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
title_short Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
title_sort revised guidelines for coronavirus disease 19 management in hematopoietic cell transplantation and cellular therapy recipients (august 2022)
topic Guideline
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464362/
https://www.ncbi.nlm.nih.gov/pubmed/36103987
http://dx.doi.org/10.1016/j.jtct.2022.09.002
work_keys_str_mv AT diovertiveronica revisedguidelinesforcoronavirusdisease19managementinhematopoieticcelltransplantationandcellulartherapyrecipientsaugust2022
AT boghdadlyzeinabel revisedguidelinesforcoronavirusdisease19managementinhematopoieticcelltransplantationandcellulartherapyrecipientsaugust2022
AT shahidzainab revisedguidelinesforcoronavirusdisease19managementinhematopoieticcelltransplantationandcellulartherapyrecipientsaugust2022
AT waghmarealpana revisedguidelinesforcoronavirusdisease19managementinhematopoieticcelltransplantationandcellulartherapyrecipientsaugust2022
AT abidimaheenz revisedguidelinesforcoronavirusdisease19managementinhematopoieticcelltransplantationandcellulartherapyrecipientsaugust2022
AT pergamsteven revisedguidelinesforcoronavirusdisease19managementinhematopoieticcelltransplantationandcellulartherapyrecipientsaugust2022
AT boeckhmichael revisedguidelinesforcoronavirusdisease19managementinhematopoieticcelltransplantationandcellulartherapyrecipientsaugust2022
AT dadwalsanjeet revisedguidelinesforcoronavirusdisease19managementinhematopoieticcelltransplantationandcellulartherapyrecipientsaugust2022
AT kambojmini revisedguidelinesforcoronavirusdisease19managementinhematopoieticcelltransplantationandcellulartherapyrecipientsaugust2022
AT seosusan revisedguidelinesforcoronavirusdisease19managementinhematopoieticcelltransplantationandcellulartherapyrecipientsaugust2022
AT chemalyroyf revisedguidelinesforcoronavirusdisease19managementinhematopoieticcelltransplantationandcellulartherapyrecipientsaugust2022
AT papanicolaougenovefaa revisedguidelinesforcoronavirusdisease19managementinhematopoieticcelltransplantationandcellulartherapyrecipientsaugust2022

Ejemplares similares